FDA Accepts uniQure's Huntington's Gene Therapy

The agency will review the Dutch developer's AMT-130 application under its accelerated approval pathway after a prior trial failed to slow disease progression.

Updated on Nov. 2, 2026 in Biotech

Flat-color editorial illustration of a clear glass vial of amber liquid beside a twisted translucent helix on a navy and cream field, evoking a gene therapy under regulatory review. — The FDA agreed on Tuesday to review uniQure's gene therapy AMT-130 for Huntington's disease under its accelerated approval pathway, with a decision due by May 1, 2027. AI Illustration. Upload story photo >

The FDA accepted uniQure's application for AMT-130, its gene therapy for Huntington's disease, after reversing course on an earlier rejection. The agency will decide on the application by May 1, 2027.

Why it matters

The review follows a four-year trial in which AMT-130 failed to slow disease progression, and uniQure's shares fell sharply afterward. The FDA's reversal and faster review give patients and investors a pathway that relies on early evidence rather than a completed trial.

The application rests on early- to mid-stage results from 51 treated patients compared with an external Huntington's disease database, and the follow-up trial will enroll 200 patients, two-thirds receiving the gene therapy. Whether these early findings hold up in the larger trial has not yet been determined.

The players

uniQure

A Dutch gene therapy developer that submitted the AMT-130 application to the FDA.

U.S. Food and Drug Administration

The federal agency responsible for reviewing and approving new drugs and gene therapies in the United States.

The details

uniQure, a Dutch gene therapy developer, submitted the application for AMT-130 after the treatment failed to slow disease progression in a four-year trial. The FDA is reviewing the application under its accelerated approval pathway, which permits earlier approval on preliminary evidence while requiring confirmation of benefit in later studies.

November 2, 2026: FDA accepts uniQure's AMT-130 application.
By year-end 2026: uniQure plans to begin US patient screening for a 200-patient follow-up trial.
May 1, 2027: FDA decision deadline on AMT-130.

Big Picture

The review applies the FDA's accelerated approval pathway, which lets the agency approve treatments for serious diseases on early evidence while requiring confirmation in later studies. Here the pathway is being used for a gene therapy whose earlier trial did not meet its primary goal.

For Huntington's patients and families, the review could lead to a gene therapy option sooner than a full trial would allow, though the approval would rest on early evidence. Patients considering participation in the follow-up trial would receive gene therapy or standard care, with two-thirds in the treatment group.

The takeaway

Approval on early evidence is a faster route, but its value depends on whether the results hold in the larger follow-up trial. Readers tracking Huntington's treatments should watch the FDA's May 1, 2027 decision.

What happens next

The FDA is considering a meeting of outside experts to discuss the application, and uniQure plans to begin US patient screening for its 200-patient follow-up trial by year-end 2026. The agency's decision deadline is May 1, 2027.